BeiGene Corp (ONC) Forward P/S Multiple

Public company logo of BeiGene (ONC)

An international network of clinics and unique molecules create barriers to entry for competitors, while the expansion of Brukinsa drives current growth. The projected P/S multiple smooths out market noise, and its current value is 5.30. The integration of Asian research with the Western market transforms BeiGene Ltd (ONC) into a key hub for blood cancer therapy, bridging the gap between science and commerce.

BeiGene - ONC Market Cap to Future Revenue Ratio (period 07/04/2022 - 11/13/2026)

ONC (BeiGene Oncology): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price BeiGene|ONC - Analyst Median Target
- market capitalization details:
Market Capitalization BeiGene Oncology|ONC - Full Takeover Company Value
- issuer book value statistics:
Book Value per Share BeiGene|ONC - Total Stockholders' Equity|Market Value to Book Value Ratio beigene.com|ONC - Total Business Assets
- debt and liquidity details:
Total Debt to Capital BeiGene Ltd|ONC - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio BeiGene Ltd|ONC - Aggregate Debt Obligations|Debt to Book Capitalization Ratio BeiGene Oncology|ONC - Company Long-Term Debt|Company Current Liabilities BeiGene|Quick Ratio beigene.com
- financial results and valuation multiples details:
ONC - Company Profit|Expected Profit BeiGene Ltd|ONC - Market Cap to Earnings|Future Price to Earnings BeiGene Corp|ONC - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple BeiGene Oncology|ONC - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) BeiGene|ONC - Net earnings per share for the last 12 months|Quarterly EPS earnings growth beigene.com|ONC - Earnings growth in current year|Net earnings per share growth forecast for next year BeiGene Ltd
- revenue and sales details:
ONC - Company Sales Volume|Projected Sales Volume BeiGene|ONC - Market Cap to Revenue|Forward P/S Multiple BeiGene Oncology
Summary company analysis:ONC (BeiGene)
Product sample of beigene.com

Innovative drugs from BeiGene Ltd (ONC) secure the company's leadership in oncology, yet geopolitical friction between the US and China creates uncertainty regarding future sales. By analyzing the forward P/S ratio, an investor assesses current capitalization relative to expected revenue for the coming year. This indicator helps determine the asset's level of overboughtness and evaluate market expectations in light of regulatory risks across Western markets.

Who BeiGene Ltd competes with

Forward P/S Multiple HALO (Halozyme)|Market Cap to Expected Sales Ratio Revolution Medicines Inc (RVMD)|Ascentage - Forward P/S Multiple|Projected Price to Revenue CG Oncology Therapeutics (CGON)|URGN: Forward P/S Multiple|Market Cap to Future Revenue Ratio bicara.com (BCAX)|Price-to-Projected Revenue Ratio Personalis|Market Cap to Projected Revenue ERAS (Erasca Inc)|Forward P/S Multiple DCTH|YMAB - Market Cap to Future Revenue Ratio|Aura Biosciences, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales CADL|ARAY - Price-to-Projected Revenue Ratio|SLS: Price-to-Projected Revenue Ratio|ACTU (Actuate Therapeutics, Inc) - Forward Price-to-Revenue Multiple|CTOR: Price to Expected Revenue Ratio|HURA (TuHURA Biosciences Inc.) - Forward P/S Multiple|Market Cap to Projected Revenue TARA (protaratx.com)|Price-to-Projected Revenue Ratio Fate Therapeutics (FATE)|WHWK - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio TScan Therapeutics, Inc. TCRX|CSBR: Market Cap to Projected Revenue|XBiotech USA - Forward P/S Multiple|CEL-SCI Corporation (CVM) - Forward Price-to-Revenue Multiple|OSTX: Forward P/S Multiple|Forward Price-to-Revenue Multiple radiopharmtheranostics.com|ARTV (Artiva Biotherapeutics Inc.) - Forward P/S Multiple|Forward P/S Multiple Adlai Nortye Limited|Price-to-Projected Revenue Ratio Veru Inc. (VERU)|tempesttx.com - Market Cap to Projected Revenue|Forward P/S Multiple XLO (Xilio Therapeutics)|RENB - Forward Price-to-Revenue Multiple|Mural Bio - Forward P/S Multiple|Market Cap to Future Revenue Ratio Kairos Pharma Ltd|onkuretherapeutics.com (OKUR) - Price-to-Projected Revenue Ratio|CytoMed Therapeutics Limited - Forward Price to Sales|Forward Price-to-Revenue Multiple CRIS|APLM: Forward Price to Sales|Forward P/S Multiple THAR|Forward Price-to-Revenue Multiple advanbiomed.com ADVB|Genprex, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple Calidi Biotherapeutics Inc. CLDI|SBFM - Price-to-Projected Revenue Ratio|Forward Price to Sales XBIO (Xenetic Biosciences)|SLRX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Kitov Pharma (PPBT)|AONC (American Oncology Network Inc) - Forward P/S Multiple|Price-to-Projected Revenue Ratio BGNE|Forward P/S Multiple CKPT|ELEV - Market Cap to Future Revenue Ratio|Forward P/S Multiple ICAD (iCAD)|Market Cap to Expected Sales Ratio Ikena Oncology Inc. (IKNA)|Notable Labs, Ltd. - Forward P/S Multiple|Projected Price to Revenue Viracta Therapeutics (VIRX)|MOR: Forward P/S Multiple|Market Cap to Future Revenue Ratio NAYA Biosciences Inc (NAYA)|Price-to-Projected Revenue Ratio Ascentage Pharma Group Ltd